Literature DB >> 8567116

Lu-ECAM-1-mediated adhesion of melanoma cells to endothelium under conditions of flow.

D J Goetz1, M E el-Sabban, D A Hammer, B U Pauli.   

Abstract

Lu-ECAM-1 is a lung-derived, venular endothelial cell adhesion molecule. It promotes the selective adhesion of lung-metastatic B16-F10 melanoma cells to endothelium under static conditions and mediates colonization of the lungs by the same tumor cells. To test whether Lu-ECAM-1 by itself is sufficient to cause vascular arrest of B16-F10 cells, we measured here under conditions of flow tumor cell adhesion to endothelia that express different amounts of Lu-ECAM-1 on their surfaces. At physiological shear stresses, adhesion of B16-F10 melanoma cells to endothelia correlates positively with the amount of Lu-ECAM-1 expression on the endothelial cell surface and inversely with the level of the applied shear stress. Tumor cell trajectories are biphasic; i.e., B16-F10 melanoma cells initially move along the endothelial surface with a velocity similar to the theoretical velocity, then arrest within a fraction of a second. Arrest is permanent for most B16-F10 melanoma cells at all shear stresses tested. Tumor cells never engaged in a rolling motion prior to arrest. Masking of the Lu-ECAM-1 ligand on the surface of B16-F10 melanoma cells with soluble Lu-ECAM-1 impedes arrest of tumor cells on the surface of the test endothelium. Purified Lu-ECAM-1 also mediates B16-F10 arrest, but arrest is mostly transient at shear stresses of 0.59 dynes/cm2 and higher, implying adhesion by single receptor/ligand bonds. Our data suggest that Lu-ECAM-1 plays a critical role in the recognition and initial arrest of murine melanoma cells in lung venules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8567116     DOI: 10.1002/(SICI)1097-0215(19960117)65:2<192::AID-IJC11>3.0.CO;2-G

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.

Authors:  Tridib Bhowmick; Erik Berk; Xiumin Cui; Vladimir R Muzykantov; Silvia Muro
Journal:  J Control Release       Date:  2011-09-16       Impact factor: 9.776

Review 2.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

Review 3.  Targeting therapeutics to endothelium: are we there yet?

Authors:  Raisa Yu Kiseleva; Patrick M Glassman; Colin F Greineder; Elizabeth D Hood; Vladimir V Shuvaev; Vladimir R Muzykantov
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

4.  Determining beta2-integrin and intercellular adhesion molecule 1 binding kinetics in tumor cell adhesion to leukocytes and endothelial cells by a gas-driven micropipette assay.

Authors:  Changliang Fu; Chunfang Tong; Manliu Wang; Yuxin Gao; Yan Zhang; Shouqin Lü; Shile Liang; Cheng Dong; Mian Long
Journal:  J Biol Chem       Date:  2011-08-12       Impact factor: 5.157

5.  Dynamic Switch Between Two Adhesion Phenotypes in Colorectal Cancer Cells.

Authors:  Yue Geng; Siddarth Chandrasekaran; Sivaprakash Agastin; Jiahe Li; Michael R King
Journal:  Cell Mol Bioeng       Date:  2013-11-14       Impact factor: 2.321

6.  Inducing apoptosis in rolling cancer cells: a combined therapy with aspirin and immobilized TRAIL and E-selectin.

Authors:  Kuldeepsinh Rana; Cynthia A Reinhart-King; Michael R King
Journal:  Mol Pharm       Date:  2012-07-02       Impact factor: 4.939

Review 7.  Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm.

Authors:  Melissa Howard; Blaine J Zern; Aaron C Anselmo; Vladimir V Shuvaev; Samir Mitragotri; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2014-05-07       Impact factor: 15.881

8.  Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion.

Authors:  Yue Geng; Siddarth Chandrasekaran; Jong-Wei Hsu; Mishka Gidwani; Andrew D Hughes; Michael R King
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.